TIFFANY JORDAN: Open Payments
NPI 1972228468 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,812 in 140 payments from 12 companies in 2025. Trend: 2023 $2,665 · 2024 $3,313 · 2025 $3,812
Food & beverage: $3,701Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 26 | $919 |
| Neurocrine BioSciences, Inc. | 20 | $543 |
| Alkermes, Inc. | 16 | $518 |
| E.R. Squibb & Sons, L.L.C. | 18 | $494 |
| Otsuka America Pharmaceutical, Inc. | 23 | $430 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $289 |
| Vanda Pharmaceuticals Inc. | 5 | $180 |
| Janssen Pharmaceuticals, Inc | 7 | $142 |
| Axsome Therapeutics, Inc. | 5 | $128 |
| ABBVIE INC. | 6 | $104 |
Products named: INGREZZA, UZEDY, COBENFY, ARISTADA, CAPLYTA, AUSTEDO XR, LYBALVI, REXULTI.
Industry payments across LA — which companies pay providers there.
